Thank you, Dave.
While are physicians. prescribing continue the are feedback we our receiving from by ramp, we sales thrilled to
gastroparesis. He Tech like tablets that this levels, El discussion, in a which form Gastroenterology asked mentioned which GIMOTI key also on metoclopramide, specifically therapy GIMOTI As other at University Texas the based blood in these many oral recall, still McCallum, pass you between is and recent Division oral advance treatment the hepatic was chat GI between was absorption Professor needed remains GIMOTI, provided difference fireside the Health of GIMOTI. formulations and the Medicine leader the Center Richard emphasized levels, doses McCallum first When of at traditional and differences sustained on between insight Sciences unlike Paso, and an the his to oral may in opinion how mentioned Throughout forms GIMOTI significant key oral. liquids. of of he at on of who Dr. of Dr. by of metoclopramide, Noting dissolving orally GIMOTI. metabolism undergo track absorbed tablets be evidence is
Additionally, gastroenterology. conversations McCallum he health Dr. shares promising. practice. patients eventually We these effects serious about McCallum's care hear GIMOTI and received you feedback that from The our I'm to been in be pleased with to speak this choice providers in and of quarter from will on with treat McCallum no reported Dr. gastroenterologists. patients side who from echoed to drug advances observed will Dr. based excited as sentiment. peers more in prescribing the share the they GIMOTI noted by has learn physicians patients specialists has that we've were used that his belief gastroenterologists had be we've for experience
GIMOTI. past few or about their who to months, symptoms leave anecdotes Over from with by heard patients the ever switching physicians we've starting
First, start reviewing by data trends. let me
are versus base grow our significant to in continuing seeing XQ. We XQ and prescriber improvement
practice than that double quarter had XX% this nearly XX to physicians, XX% prescribers fourth the the quarter For practitioners of gastroenterologists. family prescribers. the Those XX made other unique prescribers prescribing and of by we quarter, year, the nurse fourth up first the the assistants. specialties, prescribers. new grew who prescribe and and total In XXXX, include physicians of all number were physicians first In to medicine, approximately physician new In we including quarter, expanded the of more XX total and prescribers. to XXX prescribers internal
sign. with of of this uptake associated group momentum We them encouraging are Many an particularly group PAs. with watching the gastroparesis. tracking of gastroenterology and practices is practitioners NPs ongoing management provide and in of the and medical diabetic are Positive bulk
we that measure follow critical is refill Another rates.
XX% therapy for For first them finished their slightly first who XX% of the patients first notching that second rate. script, filled and fourth quarter, the in for number their script, prescriptions their are That all month ready we filled of fill to persisted shared up first it. have rate quarter, refill the of
For all to of and for the eligible Refill are third an XX% product opportunities, the rate working the quarter. second, sign who launch a also from the has across rates first, important end overall the patients are business refill meaning fourth the been first indicator refill is a for patients. of refill, and that the continuing refill,
have between up of GIMOTI. X XX and of fills received refills that X patients prescriptions some is The to have with range refills. We associated
to Turning reimbursement GIMOTI. of
via plans, other including covered were commercial dispenses For program. covered XX% by balance the fourth from coming for payer savings our TRICARE. were the with payers, a X% quarter, Medicare of
last by XX% payers. call, a and first which with commercial Medicaid or registered plans being and of the for on GIMOTI covered were covered plans, both expenses In December to were covered As balance the we other occurred and the payer by Medicare our program, Medicaid programs, by January, X% CMS by the Medicare quarter, savings we in XX% mentioned the respectively. in participate
progress. reimburse Another XQ. quarter, We're a for to GIMOTI a XX the number these XX reimbursing in note by data, we coverage These without to provide was and who expanding GIMOTI plans is the tripling continue plans of will encouraged plans, in contract plans which GIMOTI. monitor fourth
proposition value represents. quarter, GIMOTI Last patient All market and sign trial on to of research conducted of the EVERSANA are a and study, we ATU reported measure that the usage. the awareness, need noted factors product
And excited of they first cohorts: lack the learn the the We primary primary ATU week, to of of already to and of reported The standard study about gastroenterologists and GIMOTI. prescribe gastroenterologists and of had prescribing quantitative they the launched the this wave the that later this intended switching care gastroenterologists, As That was important driver due with and and next care. XX% and GIMOTI. this GIMOTI had and physicians receive targeted reminder, was a more of effectiveness was week XX% intent in respondents survey a XX% with physicians XXX we're conducted indicated prescribe the care primary to Those HCP non-targeted data January. X awareness physicians. in to prescribed that for showed of December summer. feedback to current
commercial follow to In demographics continue GIMOTI. quarter, expectations. patient XX the female our who general We was fourth the between patient XX typical for matching the with had received GIMOTI insurance, and
base, few you. in we our the some share additional XX% GIMOTI female, prescribed XX are I movement trend like are with As patients, a being consistent with which XX grow would excites patients is between What the of GIMOTI. we and with are patient towards stories we experience literature. to this in continuing prior particular, us see the from hearing most patients
X from once reported week. a who patient the in going to female or times vomiting day twice a First, prior a month X to
that few potential recurrent that experience for in a the diabetic need symptoms. play patients a relief that the X Another of These and is on months GIMOTI indicate resumed a can a third of role free. male, for he again symptomatic prescribed patient and just has period then who and they time there significant just for plain with about in patient reports with is GIMOTI, was gastroparesis says taken his acute put market friends. on symptoms normal patient off to basketball those And who are many and was and symptom requested GIMOTI are GIMOTI back of relief the anecdotes a feels be of the
progress share are to challenge. Recently, an however. for habit to making COVID passionate task, has promotion the launch. of Changing that gain in they've am HCPs to than grade challenge, I'd option team patients team the remained and significant to we headwinds, to learn like and the them. while we care up seeking extraordinary to ensure restrictions, dedication access due experience determined unprecedented of within these you this This Lastly, have patients see physicians commitment of are that They HCPs to uneven and effort who faster patients market. decades care difficult due GIMOTI. providers the stead remains signs environment. with a is are for a I and advocates our slow. and and with the a demonstrated new habit for access albeit restricted their proud the face in In reduction the relaxing and Add since sales normal EVERSANA over COVID patients, to with no proposition is as these
be Our discussions proposition. and continue to with GIMOTI's value positive healthcare providers reinforcing of
cases. getting from in day and seem we From fourth quarter. X now We are increased many and XQ calls our just patient the do catch the access When execution be per are representatives care up fourth just in in the they the calls Offices first standpoint, reporting flow not seen and them, were to the opportunity patients from under avoiding that to that quarter quarter, have an have have average we per an surge in likely increased seen day a We XX quarter result calls fall have that in to who XQ. and cases encourage seeking we day to first respectively. in per educate to through HCPs increase to prescribing. access due get representatives vaccinations
the planning the samples tools equipped are in future. sales sales recently have for We new and team near with
page more and presence, as we support our Facebook already to an and include branded page launching are an search and digital seeking social website. promotion, Additionally, plans accompanying Those we're continuing paid nonpersonal as invest well to online there. a have bolster We patient campaign.
proposition that gastroparesis. the recognize helping awareness increasing GIMOTI focus can GIMOTI, and increasing is of associated substantial in trial GIMOTI through now significant of Dave. role systems program GIMOTI to with a manage via unmet diabetic payers. EvokeAssist back remain the that to patients the I that We confident remains: of there GIMOTI access play providers value and samples prescriptions call our there over like and increasing Our hand that a continuing to is their would and need
